Thr454

Site Information
RAPIIAVtRNPQtAR SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 23132420

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 2 , 3 ) , mutation of modification site ( 1 ) , western blotting ( 1 )
Disease tissue studied:	esophageal cancer ( 3 ) , esophageal carcinoma ( 3 ) , liver cancer ( 1 ) , lung cancer ( 1 ) , non-small cell lung cancer ( 1 ) , non-small cell lung adenocarcinoma ( 1 )
Relevant cell line - cell type - tissue:	A549 (pulmonary) ( 1 ) , HEK293T (epithelial) ( 1 ) , HeLa (cervical) ( 1 , 2 ) , HepG2 (hepatic) ( 1 ) , Kyse180 (esophageal) ( 3 )

Downstream Regulation
Effects of modification on PKM:	enzymatic activity, induced ( 1 ) , protein stabilization ( 1 )
Effects of modification on biological processes:	carcinogenesis, induced ( 1 ) , cell growth, induced ( 1 ) , transcription, induced ( 1 )

References
1	Yu Z, et al. (2013) Proviral Insertion in Murine Lymphomas 2 (PIM2) Oncogene Phosphorylates Pyruvate Kinase M2 (PKM2) and Promotes Glycolysis in Cancer Cells. J Biol Chem 288, 35406-16 24142698 Curated Info
2	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
3	Tucker M (2010) CST Curation Set: 9227; Year: 2010; Biosample/Treatment: cell line, Kyse180/untreated; Disease: esophageal carcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY Antibodies Used to Purify Peptides prior to LCMS: Phospho-Tyrosine Mouse mAb (P-Tyr-100) Cat#: 9411, PTMScan(R) Phospho-Tyr Motif (Y*) Immunoaffinity Beads Cat#: 1991 Curated Info